The permission to market the drug was granted for the treatment of
cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory
Distress Syndrome patients due to COVID-19.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/health-ministry-decides-against-including-itolizumab-in-clinical-management-protocols-for-covid-19/articleshow/77185259.cms
No comments:
Post a Comment